To date, key developments of cancer vaccines expressing differentiation antigens include gp100-based vaccines against metastatic melanoma and Sipuleucel-T (Provenge), a prostatic acid phosphatase-based cancer vaccine which is currently in use to treat prostate cancer patients. This evidence concerns the gene ACP3 and prostate carcinoma.